The pharma companies AbbVie (headquartered in North Chicago, Illinois in the United States) and Gedeon Richter Plc. (headquartered in Budapest, Hungary) have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. A statement on the website of the Budapest Stock Exchange highlights that this collaboration […]

The Hungarian pharma company Gedon Richter’s partner AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for […]

AbbVie and Gedeon Richter Plc. have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter […]

AbbVie, the partner company of the Hungarian pharmaceutical firm Gedeon Richter Plc., has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. The submission is supported by results from […]

Gedeon Richter Plc. has announced that it extended its existing licensing agreement with AbbVie, originally dated 2004, for the development and commercialization of its own-developed molecule, cariprazine. The initial agreement covered the territories of the USA and Canada and was extended in 2019 to include certain countries in Latin America. The present agreement further expands […]